Whilst our study has identified the protein binding target landscape for azacitidine and decitabine in KMT2A-rearranged infant ALL cells, further studies are required to functionally validate the biological effect of these interactions. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.